RAREHealthcare · BiotechnologyThe 20 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. hold a median 12-month price target of $50 — +236.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 2 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Ultragenyx Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (84): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RARE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +236.7% from it.
Of the 20 most recent actions, 11 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | Wells Fargo | Maintains | Overweight | $46 → $50 |
| 25 Aug 2026 | JP Morgan | Maintains | Overweight | $75 → $80 |
| 21 Aug 2026 | Morgan Stanley | Maintains | Overweight | $67 → $74 |
| 20 Aug 2026 | Canaccord Genuity | Maintains | Buy | $81 → $83 |
| 20 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $96 → $103 |
| 20 Aug 2026 | Citigroup | Maintains | Buy | $45 → $58 |
| 20 Aug 2026 | Wells Fargo | Maintains | Overweight | $45 → $46 |
| 10 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 5 Aug 2026 | Wells Fargo | Maintains | Overweight | $47 → $45 |
| 4 Aug 2026 | Guggenheim | Maintains | Buy | $43 → $35 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $35 → $40 |
| 21 May 2026 | Cantor Fitzgerald | Maintains | Overweight | $84 → $96 |
| 8 May 2026 | Guggenheim | Maintains | Buy | $52 → $43 |
| 8 May 2026 | Wedbush | Maintains | Neutral | $27 → $26 |
| 6 May 2026 | Wedbush | Maintains | Neutral | $27 → $26 |
| 6 May 2026 | Wells Fargo | Maintains | Overweight | $45 → $47 |
| 29 Apr 2026 | Barclays | Maintains | Overweight | $44 → $43 |
| 16 Apr 2026 | Morgan Stanley | Maintains | Overweight | $50 → $67 |
| 24 Mar 2026 | Goldman Sachs | Downgrade | Neutral | $61 → $25 |
| 12 Mar 2026 | JP Morgan | Maintains | Overweight | $120 → $74 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RARE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Ultragenyx Pharmaceutical, Inc. returned −52.9% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 36% of US stocks
Cheaper than 98% of US stocks
Cheaper than 82% of US stocks
Higher than 77% of US stocks
Higher than 65% of US stocks
Higher than 93% of US stocks
Higher than 19% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ultragenyx Pharmaceutical, Inc. has a market value of $2.6B and an enterprise value of $3.5B.
Revenue in the twelve months to 30 June 2026: $717.2M. The latest quarter grew 28.1% year on year.
Net income over the same four quarters: −$586.0M, a −81.7% net margin.
Diluted earnings per share, trailing twelve months: $−5.84.
Free cash flow in the twelve months to 30 June 2026: −$494.0M.
Trailing P/E: −4.6×; forward P/E: 5.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Ultragenyx Pharmaceutical, Inc. employs 1,371 people — $523K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ultragenyx Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ultragenyx Pharmaceutical (RARE) reported earnings 30 days ago, and its stock has since risen 6.4%. The article examines what might come next for the company following that earnings report.
Why it matters — RARE watchers would track stock movement after an earnings report as an indicator of how the market is responding to the company's latest financial results.
Ultragenyx's phase III Angelman syndrome study failed to meet key efficacy goals, causing the company's stock to drop 46% and raising questions about the future of apazunersen.
Why it matters — A RARE watcher would care because the failed pivotal trial jeopardizes the prospects of a key pipeline candidate, apazunersen, and triggered a major share-price decline.
Martin Shkreli, known as Pharma Bro, stated that Ultragenyx Pharmaceutical is undervalued and a potential acquisition target for rare-disease peers such as BioMarin Pharmaceuticals, citing the company after a trial setback.
Why it matters — Ultragenyx watchers may see this as notable because a well-known investor is suggesting the company could be an attractive takeover candidate following its recent trial setback.
Ultragenyx reported late-stage clinical trial failures for apazunersen, its Angelman syndrome therapy, causing its stock to fall on Thursday. The company is reviewing the program's future and planning significant corporate expense reductions in response.
Why it matters — RARE watchers would note the Phase 3 failure threatens a key pipeline asset and signals cost-cutting and potential strategic changes at the company.
Ultragenyx Pharmaceuticals' stock fell 47% following a drug trial failure. In response, the company plans to cut costs while continuing to focus attention on its growing commercial business.
Why it matters — A RARE watcher would care because the trial failure and sharp stock decline represent a major setback, while the company's cost-cutting plan and commercial business outlook shape its path forward.
The 20 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. have a median 12-month price target of $50, with estimates ranging from $28 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering Ultragenyx Pharmaceutical, Inc., 18 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ultragenyx Pharmaceutical, Inc. 47 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Ultragenyx Pharmaceutical, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (84 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +236.7% from the last close, and Ticker Nerd's factor model ranks Ultragenyx Pharmaceutical, Inc. 47 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ultragenyx Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $103 over the next 12 months.
Ultragenyx Pharmaceutical, Inc. returned -52.9% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?". Ultragenyx Pharmaceutical (RARE) reported earnings 30 days ago, and its stock has since risen 6.4%. The article examines what might come next for the company following that earnings report.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Its current portfolio includes approved medicines and other therapies designed to address serious conditions with limited treatment options, spanning metabolic, skeletal, and other inherited disorders. The company works across multiple modalities, including biologics, small molecules, gene therapy, and nucleic acid-based approaches, to target diseases where the underlying biology is well understood and patient need is high. Ultragenyx serves patients through marketed products such as therapies for X-linked hypophosphatemia, long-chain fatty acid oxidation disorders, mucopolysaccharidosis, and homozygous familial hypercholesterolemia. Headquartered in Novato, California, Ultragenyx plays a specialized role in the rare-disease market by combining commercialization capabilities with ongoing research and development in genetic medicine.
CEO Dr. Emil D. Kakkis M.D., Ph.D. · 1,371 employees · United States · https://www.ultragenyx.com
